Endothelin‐1‐induced venous contraction is maintained in DOCA‐salt hypertension; studies with receptor agonists
- 1 September 2002
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (1), 69-79
- https://doi.org/10.1038/sj.bjp.0704831
Abstract
1. Deoxycorticosterone acetate (DOCA) salt hypertension is associated with an endothelin-1 (ET-1)-dependent increase in arterial resistance and mean circulatory filling pressure. Contraction of endothelium-intact arteries and veins from sham and DOCA-salt hypertensive rats to agonists of the ET(A) (ET-1((1-31))) and ET(B) receptor (sarafotoxin 6c; S6c) was investigated in tissue baths as was expression of mRNA for ET-1 and mRNA and protein for the ET(A) and ET(B) receptor. 2. ET-1((1-31)) contracted aorta and vena cava from sham rats with a 30 fold lower potency than ET-1. Contraction was not altered by the ET(B) receptor antagonist BQ788 (100 nM) but was abolished by the ET(A) receptor antagonist ABT-627 (30 nM). 3. In DOCA-salt thoracic aorta, maximum contraction to ET-1 and ET-1((1-31)) was reduced (36.6 +/- 6.3 and 13.3 +/- 4.4% of sham response, respectively); aorta did not contract to S6c. 4. In vena cava from DOCA-salt rats, contraction to ET-1 and ET-1((1-31)) was not reduced compared to sham contraction; vena cava from sham and DOCA-salt rats contracted to S6c with a similar potency. 5. Real time RT-PCR revealed that prepro ET-1 mRNA was increased 6.6 +/- 3.3 fold and 8.7 +/- 3.9 fold greater in DOCA-salt aorta and vena cava, respectively, compared to sham. Vena cava expressed a higher content of ET(A) and ET(B) receptor mRNA than aorta (P < 0.05), but no differences were observed between sham and DOCA-salt tissues. ET(A) and ET(B) receptor protein was identified in all tissues. Immunoreactive ET(A) receptor, observed as a 65, 30 and 28 kDa bands, was expressed 400% greater in DOCA-salt aorta compared to sham, but was not altered in vena cava. Immunoreactive ET(B) receptor, observed as 120, 45 and 30 kDa bands, tended to be higher in vena cava compared to aorta, but was not different in sham and DOCA-salt vena cava. 6. These results suggest that ET(A) receptor function is impaired in aorta but not vena cava of DOCA-salt rats. The ET(B) receptor was present in the aorta but, unlike in veins, does not mediate contraction directly. A sustained response to ET-1 in the venous circulation may contribute to the elevated blood pressure in the DOCA-salt model.Keywords
This publication has 44 references indexed in Scilit:
- Vasoconstrictor activity of novel endothelin peptide, ET‐1(1 – 31), in human mammary and coronary arteries in vitroBritish Journal of Pharmacology, 2001
- A Novel 31-Amino-Acid-Length Endothelin, ET-1(1–31), Can Act as a Biologically Active Peptide for Vascular Smooth Muscle CellsBiochemical and Biophysical Research Communications, 2000
- Regulation and Intracellular Trafficking Pathways of the Endothelin ReceptorsPublished by Elsevier ,2000
- Different Contributions of Endothelin-A and Endothelin-B Receptors in the Pathogenesis of Deoxycorticosterone Acetate–Salt–Induced Hypertension in RatsHypertension, 1999
- Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy.Hypertension, 1994
- Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats.Hypertension, 1993
- Endothelin ETA and ETB Receptors Mediate Vascular Smooth-Muscle ContractionJournal of Cardiovascular Pharmacology, 1993
- Endothelin vascular receptors and responses in deoxycorticosterone acetate-salt hypertensive rats.Hypertension, 1992
- Pharmacology of Endothelin-1 in Isolated VesselsJournal of Cardiovascular Pharmacology, 1989
- The loss of endothelium-dependent vascular relaxation in hypertension.Hypertension, 1986